Medical Affairs: Strategic Lifecycle Partner

• Decoding country-by-country HTA differences and their impact on launch timelines
• Preparing comparative data packages aligned with EU national requirements
• Strategizing launch sequencing to avoid reimbursement bottlenecks
• The evolving role of Medical Affairs as a strategic partner across the development lifecycle, particularly how earlier involvement can improve trial design, strengthen evidence generation, and ultimately accelerate the path to patients

Speakers:

Joao Costa

Global Associate Medical Director Immunology

Sanofi